<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973842</url>
  </required_header>
  <id_info>
    <org_study_id>Agonist triggering dose</org_study_id>
    <nct_id>NCT01973842</nct_id>
  </id_info>
  <brief_title>Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients</brief_title>
  <acronym>ATD</acronym>
  <official_title>Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients Undergoing Ovarian Stimulation for IVF With GnRH Antagonists and Recombinant FSH.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eugonia IVF Unit, Athens, Greece</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to investigate whether the dosage of the GnRH agonist used for
      triggering final oocyte maturation affects the maturity of the oocytes retrieved in high risk
      for OHSS patients undergoing ovarian stimulation for IVF using GnRH antagonists and
      recombinant FSH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three different doses of GnRH agonist (0.1mg, 0.2mg or 0.4 mg) will be used randomly to
      trigger final oocyte maturation. The primary outcome measure will be the percentage of mature
      oocytes retrieved.

      Secondary outcomes will include: number of oocytes retrieved, oocyte recovery rate (number of
      oocytes retrieved/ number of follicles &gt;11mm in diameter on the day of triggering),
      fertilization rates and OHSS occurrence.

      Serum LH, FSH, E2, PRG levels will be assessed at 8-36 hours following agonist administration
      and on days 3-4-7-10 after triggering final oocyte maturation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of mature oocytes retrieved</measure>
    <time_frame>36 hours post GnRH agonst administration</time_frame>
    <description>Percentage of mature oocytes retrieved following oocyte retrieval</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total number of oocytes retrieved</measure>
    <time_frame>36 hours post GnRH agonist administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oocyte recovery rate</measure>
    <time_frame>36 hours post GnRH agonist administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>Day 1 post oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LH, FSH, E2, PRG levels</measure>
    <time_frame>8-36 hours post triggering and on days 3-4-7-10 after GnRH agonist administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of luteal phase</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OHSS occurrence</measure>
    <time_frame>16 days post triggering</time_frame>
    <description>Occurrence of ovarian hyperstimulation syndrome</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Subfertility</condition>
  <arm_group>
    <arm_group_label>0.2 mg triptorelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.2 mg triptorelin compared with 0.1 mg triptorelin and 0.4 mg triptorelin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 mg triptorelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg triptorelin compared with 0.2 mg triptorelin and 0.4 mg triptorelin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4 mg triptorelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.4 mg triptorelin compared with 0.1 mg triptorelin and 0.2 mg triptorelin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1 mg triptorelin</intervention_name>
    <arm_group_label>0.1 mg triptorelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2 mg triptorelin</intervention_name>
    <arm_group_label>0.2 mg triptorelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.4 mg triptorelin</intervention_name>
    <arm_group_label>0.4 mg triptorelin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients undergoing ovarian stimulation for IVF using GnRH antagonist
        protocol

          -  Age &lt; 40 years

          -  Anticipated high ovarian response

        Exclusion Criteria:

          -  Endometriosis &gt; than grade II

          -  One ovary
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Efstratios Kolibianakis, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unit of Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki Thessaloniki, Greece</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Efstratios Kolilbianakis, MD, MSc, PhD</last_name>
    <email>stratis.kolibianakis@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Georgios Lainas, MD</last_name>
    <email>g.lainas@yahoo.co.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eugonia IVF Unit</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trifon Lainas, MD, PhD</last_name>
      <email>tlainas@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Trifon Lainas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unit of Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Efstratios Kolibianakis, MD, MSc, PhD</last_name>
      <email>stratis.kolibianakis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Efstratios Kolibianakis, MD, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Lainas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>October 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>E.M. Kolibianakis</investigator_full_name>
    <investigator_title>Ass Professor in Obstetrics - Gynecology and Assisted Reproduction</investigator_title>
  </responsible_party>
  <keyword>GnRH agonist</keyword>
  <keyword>OHSS</keyword>
  <keyword>Triggering final oocyte maturation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

